Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
This study identifies branched-chain and aromatic amino acids as novel markers of CVD development and as an early link between diabetes and CVD susceptibility.
Cardiovascular risk is increased in obese subjects. Nevertheless, some overweight and obese remain cardiometabolically healthy (CMH), and normal-weight persons develop cardiovascular disease (CVD).
Valine and leucine were significantly higher in the obese (P<.001, P=.015, respectively), overweight (P<.001, P=.015, respectively) and lean (P=.024, P=.012, respectively) cardiometabolically abnormal compared to cardiometabolically healthy subjects. Isoleucine showed except of the lean group the same results. Taken together, BCAAs, especially valine and leucine, are proposed as a cardiometabolic risk marker independent of body mass index (BMI) category.
We validated the independent association of metabolites involved in BCAA metabolism with CAD extremes. These metabolites may be reporting on novel mechanisms of CAD pathogenesis that are independent of IR and diabetes.
Our results demonstrate that BCAAs are significantly related to CAD development. This relationship is independent of diabetes, hypertension, dyslipidaemia, and body mass index.
Circulating plasma BCAAs were positively associated with incident CVD in women. Impaired BCAA metabolism may capture the long-term risk of the common cause underlying T2D and CVD.
A total of 9584 men (age 57.4 ± 7.0 years, body mass index 27.2 ± 4.2 kg/m2) from the Metabolic Syndrome in Men study without cardiovascular disease and type 1 diabetes at baseline were included in this study. We identified alanine as a new amino acid associated with increased risk of CAD and glutamine as a new amino acid associated with decreased risk of ischemic stroke. We also confirmed that phenylalanine and tyrosine were associated with CAD, ischemic stroke, and CVD events.
We validated the independent association of metabolites involved in BCAA metabolism with CAD extremes. These metabolites may be reporting on novel mechanisms of CAD pathogenesis that are independent of IR and diabetes.
Our study aims to provide a profile of amino acid changes in the serum of patients with early-onset coronary artery disease (EOCAD) and identify potential disease biomarkers.
We have provided a serum amino acid profile for EOCAD patients and screened eight disease state-related amino acids, and we have also shown that 4-Hydroxyproline is a promising target for further biomarker studies in early-onset MI.
GABR and the arginine to ornithine ratio are associated with markers of endothelial dysfunction and increased risk of cardiovascular mortality.
GABR may serve as a more comprehensive concept of reduced NO synthetic capacity compared to systemic arginine levels. Diminished GABR and high citrulline levels are associated with both development of atherosclerotic CAD and heightened long-term risk for major adverse cardiac events.
Our results suggest that the metabolic profile of arginine, especially Arg/Cit and GABR, has independent predictive value for the presence of CAD over traditional risk factors in an outpatient setting.
We found dietary glutamine and glutamine-to-glutamate ratio were inversely related to risk of mortality, particularly cardiovascular mortality, independent of other dietary and lifestyle factors, in US men and women.
Recent evidence demonstrates that BCAAs are associated with insulin resistance, type 2 diabetes, risk of cardiovascular disease, stage I and II chronic kidney disease and ischemic stroke. Further, circulating levels of BCAAs have the potential to predict populations at risk for cardiometabolic disease, type 2 diabetes and mortality from ischemic heart disease.
Higher intakes of BCAA were associated, independently of genetics, with lower insulin resistance, inflammation, blood pressure and adiposity-related metabolites. The BCAA intake associated with our findings is easily achievable in the habitual diet.
This comprehensive compilation highlights key publications and resources focused on amino acids. These references cover various aspects such as biochemistry, metabolism, nutritional significance, diagnostics, and therapeutic applications of amino acids.
With a simple blood test we’re able to discover health conditions before symptoms even appear and then mitigate them with amino acid supplements personalised to your metabolic needs.
Amino Acid Science Ltd pioneered this technique and evidence-based algorithm to undertake human amino acid profiling that enables a comprehensive physical, mental and nutritional check-up and thereby providing personalized supplementation tailored to the needs of an individual.
MedCity, UK endorsed this business as an innovation in Digital Health in 2020.
Amino acid analysis is a laboratory technique used to analyze the types and quantities of amino acids present in blood sample. Amino acids are the building blocks of proteins and play critical roles in a wide range of biological processes, including the synthesis of proteins, neurotransmitters, and other molecules.
No, Amino acid analysis is not a new method. It has been a well-established and widely used method in biochemistry and nutrition research for many years. For the past 40 years, the HPLC and LC MS/MS methods have been used to accurately measure the levels of amino acids and metabolites that play a role in all of the body's functions.
What is new is we developed an amino acid analysis interpretation system that provides an evidence-based assessment of health and nutritional status and supplement recommendation to prevent health risks and improve physical and mental health.
This system called as AminoCheck was developed by Amino Acid Science Ltd established in Imperial College Innovation Hub, London, based on the studies of Dr. Aydın Duygu. The UK government has recognized Dr. Aydın Duygu as innovator in the field of medical technology and digital health.
AminoCheck analysis is an early warning system for future health problems or undetected diseases. Apart from health status and risks, it clearly reveals which nutrient support we need. So, you don't have to take random supplements.
Amino acid analysis can provide valuable insights into our health status and help guide nutritional and medical interventions to improve health outcomes.
Here are some examples:
The analyses performed for checkup purposes show positive results if there is a disease. Routine checkup controls such as blood tests, urine tests, and physical examinations are used to screen for a wide range of health conditions and assess overall health status. These tests typically measure markers such as cholesterol, blood glucose, liver enzymes, and kidney function.
In contrast, amino acid analysis is a more specialized test that specifically evaluates protein and amino acid metabolism that is related to all biological functions of human beings.
AminoCheck provides information about the types and quantities of amino acids present in a sample, which can be used to diagnose metabolic and psychologic disorders, monitor disease progression, and assess nutritional status.
Amino acids play a role in all of our body's functions. Even a deficiency or imbalance in a single amino acid affects the functions of other amino acids. Many factors, such as intense stress, heavy exercise, unbalanced nutrition, and sadness, can cause a decrease or imbalance in amino acid levels. Therefore, by conducting an AminoCheck analysis it is possible to obtain information about the causes of many conditions from insomnia to changes in appetite, from hair loss to depression.
AminoCheck provides advanced amino acid testing and personalised amino acid supplements to optimise health, prevent conditions, and support treatment for various health issues.
The Courtyard, 151 Sydney Street, Chelsea, SW3 6NT London
info@aminocheck.com
+44 (0) 7765 276 605
Privacy Policy | Cookie Policy | Terms and Conditions
Amino Acid Science R&D and business activities are operated under Amino Acid Science Ltd, Imperial College Translation & Innovation Hub in London, UK